Journal of Applied Pharmaceutical Science Vol. 14(08), pp 112-124, Augsut, 2024 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2024.174125 ISSN 2231-3354



Chromatographical fingerprint analysis, in *silico* investigation, and identification of hepatoprotective active compounds from *Capparis decidua* Edgwe (Forssk.)

Wadah Osman^{1,2}, Mohamed Mirghani^{2,3}, Mona Mohamed², Asmaa E. Sherif^{1,4}, Ahmed Ashour^{1,4*}, Sherouk Hussein Sweilam^{1,6} and Hassan Subki^{2,5}

¹Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz university, Al-kharj, Saudi Arabia.

²Department of Pharmacognosy, Faculty of Pharmacy, University of Khartoum, Sudan.

³Department of Pharmacognosy, Faculty of Pharmacy, International university of Africa, Khartoum, Sudan.

⁴Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

⁵Department of Pharmacognosy, Faculty of Pharmacy, Ibn Sina University, Khartoum, Sudan.

⁶Department of Pharmacognosy, Faculty of Pharmacy, Egyptian Russian University, Badr, Suez Road, Cairo, Egypt.

ARTICLE HISTORY

ABSTRACT

Received on: 24/03/2024 Accepted on: 13/06/2024 Available Online: 05/08/2024

Key words

Hexadecanoic acid, 9-octadecenoic acid (elaidic acid), 9,12,15-octadecatrienoic acid, β -sitosterol, oleanolic acid, *Capparis decidua* stem part, GC/MS, HPTLC fingerprint, *in silico* docking. Liver disorders are globally distributed with a high burden of disease costs. The methanolic extract of Capparis decidua stem part and its dichloromethane (DCM) and ethylacetate fractions showed significant hepatoprotective activity, so this study aimed to develop gas chromatography/mass spectrometry (GC/MS), high-performance thin layer chromatography (HPTLC) fingerprint profile and in silico docking of identified compounds from both fractions responsible for hepatoprotective activity. Hexadecanoic acid, 9-octadecenoic acid, 9,12,15-octadecatrienoic acid, and dihydrolinalool are known hepatoprotective and antioxidant agents that were identified from both fractions by GC/MS, they have various degrees of hepatoprotective and antioxidant properties, this is the first time to identify hexadecanoic acid in C. decidua stem. Both fractions were chromatogramed with known hepatoprotective standard compounds, they were rutin, quercetin, kaempferol, ferulic acid, oleanolic acid, and β -sitosterol; β -sitosterol and oleanolic were isolated and identified in the DCM fraction by HPTLC, but nothing of these standard compounds were identified in the ethylacetate fraction. According to International Council for Harmonization guidelines, the HPTLC fingerprint profile method was validated to confirm our isolation and identification process of β-sitosterol and oleanolic acid in the DCM fraction, also their contents were quantified and they were 9.21 and 7.73 μ g/mg, respectively, in the total dry fraction weight, this was the first time to isolate and identify oleanolic acid from C. decidua stem part. In silico docking was carried and was found that hexadecanoic acid showed significant predicted binding properties on Nrf2, p38 mitogen-activated protein kinase, and IL-1 receptor proteins. 9-octadecenoic acid (elaidic acid) showed significant predicted interactions with IL-1 receptor, Nrf2, and peroxisome proliferator- activated receptor- α (PPAR- α) proteins. Oleanolic acid showed significant predicted bindings with p65, JNK, and NF-kb. β-sitosterol showed significant predicted interaction with IL-6 α protein, while 9,12,15-octadecatrienoic acid revealed significant binding with PPAR- α protein. Therefore, we recommend considering our active compounds in the field of drug development (structure activity relationship) and the possibility of the presence of synergism if they are combined and administered together. Moreover, we recommend liquid chromatography-mass spectrometry and nuclear magnetic resonance on both fractions to search for the possibility of the presence of other hepatoprotective compounds.

*Corresponding author:

Ahmed Ashour, Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz university, Al-kharj, Saudi Arabia and Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. E-mail: ahmedadelashour @ yahoo.com

© 2024 Wadah Osman *et al.* This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

INTRODUCTION

Liver disorders are globally distributed with a high burden of disease costs, it is estimated that about 2 million cases of liver disorders occur every year, these liver disorders consist of many liver diseases (mainly inflammatory hepatitis, viral hepatitis, liver cirrhosis, and jaundice), these liver diseases- if untreated- will lead to many complications which may end with death [1]. Unfortunately, there are few drugs that are used in the treatment and management of liver disorders, most of these drugs are mainly used for alleviating symptoms of some liver disorders and their complications [2]. Despite that many herbs and natural products have shown marked hepatoprotective activity, but only silymarin (a flavono-lignan mixture obtained from Silybum marianum, Asteraceae) is widely available in the market as a hepatoprotective agent, also few natural compounds were isolated and characterized from their natural sources, hence there is a need to isolate more natural compounds with hepatoprotective activity [3,4].

Capparis decidua Edgwe (Forssk.) (Capparidaceae) is a woody plant that is widely distributed in Sudan and other tropical and sub-tropical countries [5], it has many pharmacological uses, many studies showed that it possesses anti-inflammatory, and analgesic, anti-rheumatic, anti-arthritis, anti-gout, anti-platelet aggregation, anti-diabetic, hypolipidemic, antioxidant, anti-bacterial, anti-fungal, anti-viral, and anthelmintic properties [6–11]. Many traditional uses have been recorded, the plant is used in various cases such as asthma, cough, rheumatism, swellings, toothache, stomach problems, intermittent fever, jaundice, dysentery, cardiac diseases, and some skin inflammations [12].

The hepatoprotective activity of the stem part of C. decidua had extensively been studied, both methanolic and aqueous extracts of its stem part were administered orally at doses 200 and 400 mg/kg on CCl4-induced hepatotoxicity rats, and it was found that both extracts have significant hepatoprotective activity when compared with the standard silymarin, the study suggested that this significant hepatoprotective activity may due to the presence of tannins, flavonoids, sterols, saponins, coumarins, and alkaloids [13]. In our previous study, the methanolic extract of C. decidua stem was bio-assay guided fractionated successively into dichloromethane (DCM), ethylacetate, n-butanol, and aqueous fractions, these fractions were examined on CCl₄- induced hepatotoxicity rats at dose 500 mg/kg i.p., it was found that DCM and ethyl acetate fractions showed significant hepatoprotective activity when compared with standard silymarin, while n-butanol fraction showed moderate activity, but the aqueous fraction was inactive, the : 2,2-diphenyl-1picrylhydrazyl free radical scavenging activity (RSA) of our fractions were matching with their hepatoprotective activity, the fractions showed 86, 92, 53, and 14 %RSA, respectively, while the active standard (propyl gallate) showed 92 %RSA [14], so to continue with our previous work, the aim of this study is to develop gas chromatography/mass spectrometry (GC/MS), high-performance thin layer chromatography (HPTLC)-fingerprint profile and in silico docking of both DCM and ethylacetate active fractions of methanolic extract of C. decidua stem part, as well as identification of some hepatoprotective active compounds present in both fractions.

MATERIALS AND METHOD

Materials

Plant material

The plant material (stem part of *C. decidua*, Capparidaceae) was collected from Shambat (Khartoum North) in September 2019, the plant material was authenticated by the taxonomist (Dr. Yahia Sulaiman) in the Herbarium of Medicinal and Aromatic Plants Research Institute (MAPRI), Khartoum, Sudan. The voucher herbarium specimen was deposited in the MAPRI (Sudan).

Chemicals and reagents

All chemicals and reagents used in this study were of analytical grade quality and were obtained from certified sources. DCM, methanol, n-butanol, sulphuric acid, and formic acid were obtained from SDFCL-India. Ethylacetate and toluene were obtained from Romil-England. Ethanol and chloroform were obtained from Duksan-South Korea. Vanillin was obtained from Loba-chemie-India. Rutin, quercetin, kaempferol, ferulic acid, oleanolic acid, and β -sitosterol were obtained from Sigma-Aldrich (USA).

Equipment

GC/MS equipment (Perkin Elmer model Clarus 600 T combined with single quadrapole mass spectrometer) obtained from PerkinElmer Co. (USA). Precoated silica gel 60 F254 plates are used for TLC and HPTLC techniques (Merck, Germany). CAMAG glass twin trough chamber for development (20×20) plus Camag Linomat-IV applicator for HPTLC technique plus CAMAG HPTLC scanner III (CAMAG, Muttenz, Switzerland).

Method

Preparation of the plant extracts

The collected plant material (*C. decidua* stem) was dried and ground into coarse powder form, the total weight was about 1.5 kg, it was macerated firstly by DCM and next by methanol 80%, and the extraction process was repeated for both solvents several times by changing with fresh solvent each time, both extracts were collected and dried under reduced pressure, they have kept in tightly closed containers and stored at $2^{\circ}C-8^{\circ}C$.

Fractionation of the methanolic extract of C. decidua

About 100 g of dried methanolic extract was taken and suspended in distilled water (up to 250 ml), the solution was transferred into the separatory funnel (500 ml) and about 100 ml of DCM was added; the mixture was shaken gently and allowed to stand till two immiscible layers were separated, the DCM layer was removed and the process was repeated by adding another fresh solvent several times till the DCM layer became colorless; this procedure was repeated with ethylacetate and n-butanol; finally the four fractions were dried under reduced pressure and stored in tight closed containers at $2^{\circ}C-8^{\circ}C$.

GC/MS analysis of DCM and ethyl acetate fractions

GC/MS analysis was carried out by using the Perkin Elmer model Clarus 600 T combined with a single quadrapole mass spectrometer. The chromatographic column was an Elite 5-MS column (30 m × 0.25 mm × 0.25 μ m film thickness), while the carrier gas was high purity helium, 1 μ l of DCM and ethyl acetate fractions samples were injected individually by splitless injector (split ratio 1:20), the injector temperature was 280°C. The temperature was set initially at 40°C (held for 1 minute), then was increased up to 150°C at 10°C/minute, then was further increased to 300°C at 10°C/minute. The flow rate was adjusted at 1 ml/minute. The peaks of the compounds were identified by comparing the spectra with that of the NIST 2005 (National Institute of Standard and Technology Library) and Wiley 2006 library. 29 minutes was the total time required for analyzing both samples.

TLC profile

About 15 mg of each active fraction (DCM and ethylacetate fractions) was taken and dissolved in about 3 ml of DCM and ethylacetate solvents, respectively, pre-coated silica gel 60 F254 plates were prepared (2.5×10 cm) and a spot from each fraction in separate plates was applied, several mobile phases had been tried and were prepared in well closed chromatographic jars, these mobile phases had been left for at least 20 minutes for saturation, after that all pre-coated plates had been placed inside the chromatographic jars, after development process the plates were then removed, dried, and detected under daylight, short and long UV lamps (254 and 366 nm, respectively), after that the plates were sprayed by vanillin/ H₂SO₄ (1 g of vanillin was dissolved in 80 ml of methanol 80%, and the volume was completed to 100 ml by adding H₂SO₄ 60%), they were then heated inside the oven for 10 minutes. The most proper mobile phase which gave the appropriate separation was selected for each fraction for HPTLC analysis.

HPTLC profile of DCM and ethylacetate fractions

The samples of active fractions were prepared by dissolving 20 mg from each fraction in 1 ml of methanol. The HPTLC pre-coated plates were adjusted to 20×20 cm, the silica gel used was 60 F254, the selected mobile phases were toluene: ethylacetate: methanol 9:1:1 for DCM active fraction, and toluene: ethylacetate: formic acid: n-butanol 5:4:1:1 for ethylacetate active fraction. The prepared samples were filtered



Figure 1. GC/MS spectrum of DCM fraction of methanolic extract of *C. decidua* stem part.

and 8 μ l of each sample was applied on each plate. Each plate was eluted to a distance of 8 cm at room temperature (25°C) in a specific developed solvent system. The samples were applied as bands (6 mm wide and 8 mm apart) by using a Camag Linomat IV sample applicator equipped syringe size of 25 μ l with nitrogen flow providing a delivery speed of 150 nl/second from the syringe. The standard samples of reference compounds with known hepatoprotective activity were used as markers, they were rutin, quercetin, kaempferol, ferulic acid, oleanolic acid, and β -sitosterol (the stock solution was prepared by taking accurately 2 g from each compound was dissolved in a small amount of methanol, then the volume was completed to 25 ml of methanol in a volumetric flask). The plates were

Table 1. GC/MS data of DCM fraction of methanolic extract of *C*. *decidua* stem part.

No.	Compound name	Retention time Rt (minute)	Area percentage (%)	Peak area
1	Cis-3-Hexenal	6.33	1.670	31,197
3	Dihydromyrcene	11.88	0.940	17,447
4	3-Hexen-1-OL	12.49	2.180	40,576
5	4-hydroxy-3-methyl	12.95	0.730	13,574
6	benzaldehyde	14.93	1.710	31,964
7	Hexanoic acid	15.98	0.330	6,106
8	Decanal	17.03	4.400	82,113
9	Coniferol	18.06	1.840	34,231
10	1-(2-hydroxyethyl)-	18.90	5.630	105,036
11	cyclopentene	19.31	24.540	457,685
12	Methyl ester of pentanoic	19.61	3.010	56,062
13	acid	19.90	0.950	17,666
14	N-hexadecanoic acid	20.09	8.920	166,427
15	4-Thia-alpha santalene	20.27	0.230	4,299
16	1-propoxy-hexane	20.38	0.400	7,434
17	Hexadecanoic acid	20.65	11.540	215,313
18	Palmitinic acid	20.99	10.990	205,069
19	1-ethenyl-3-(1-hexenyl)- 4-trimethyl cyclopentane	21.20	2.950	55,122
20	Cyclopropanemethanol	21.65	0.980	18,283
21	2-nitrocyclooctanone	22.44	3.700	68,987
22	Nonanoic acid	24.17	1.740	32,394
23	9.12.15-octadecatrienoic	24.34	4.720	88,016
24	acid	24.74	2.120	39,453
25	2-chloroheptylacetate Alphan-butyl malanohydroxamic acid 1,1-dimethylethyl acetic acid (e)-2-decenal 6,10-dimethyl-4-	27.70	0.830	15,433
	undecanol			

developed in a Camag twin trough glass tank pre-saturated with the mobile phase. The plate was developed horizontally in the Camag horizontal developing chamber at room temperature. The scanning was carried out under short and long wavelengths (254 and 366 nm), each plate was heated at 100°C and derivatized by vanillin/H₂SO₄ using CAMAG HPTLC scanner III. In addition, the peak areas were recorded by using WIN CATS 1.2.3. software program. For the preparation of the HPTLC fingerprint profile for DCM active fraction, the above procedure was repeated with a marker consisting of a mixture of β -sitosterol and oleanolic acid. The calibration curves of β -sitosterol and oleanolic acid were prepared accordingly with the above-mentioned procedure by using their standard solutions with aliquot concentrations ranging from 200–1,400 ng/spot.

Validation of HPTLC method

International Council for Harmonization (ICH) guidelines (2005) were regarded for the validation analytical process to confirm precision, repeatability, and accuracy. The instrumental precision was checked by repeated scanning (n=6)of the same spot of either β -sitosterol or oleanolic acid (400 ng/ spot) and expressed as a percentage relative standard deviation (% RSD). The repeatability of the method was performed by analyzing 400 ng/spot of either β-Sitosterol or oleanolic acid on the TLC plate (n = 6) and expressed as % RSD. Variability of the method was also studied by analyzing various aliquots of standard solutions containing 600, 800, and 1,000 ng/spot of either β -Sitosterol or oleanolic acid on the same day (i.e., intraday precision) and on different days (i.e., inter-day precision). The accuracy of the method was assessed by performing the recovery study method at four different ascending concentration levels (starting with 0%, 50%, 100%, and 150% addition of either β -Sitosterol or oleanolic acid).

Quantification of β *-sitosterol and oleanolic acid present in DCM active fraction*

Accurately, 20 µl of suitably diluted sample solution of DCM active fraction was applied on a pre-coated plate (n = 3), the plate was developed and scanned as mentioned in section 4.2.5, then the peak areas were recorded and the amounts of β -Sitosterol and oleanolic acid were calculated by using the calibration curve.

In silico docking of the active phyto-chemical compounds

The protein ligands responsible for hepatotoxicity (and hence for hepatoprotective activity) were determined by literature review, and the structures of the selected proteins were determined and downloaded from www.uniprot.org and from research collaboratory for structural bioinformaticsprotein data bank (www.rcsb.org), the three-dimensional chemical structures of the selected active phytochemical compounds were downloaded from PubChem web site (www.pubchem.ncbi.nlm.gov). The selected proteins were initially prepared before docking by removing all the bad steric clashes using AMBER 99 force field; MMFF94s force field parameters were adjusted for the small molecules. Next, docking studies were performed by the molecular operating environment program for each ligand as described, while other parameters were kept default (i.e., the necessary chain was deleted, the scoring function was London force and 10 conformers of the ligand were retained with highest and best score by default). Finally, the scoring configuration of the ligand-target complexes was selected on energetic grounds (Kcal/Mol), and the obtained results were presented in tabular and image forms.

RESULTS

GC/MS technique

(Fig. 1) and (Table 1) revealed the GC/MS data analysis of DCM fraction of the methanolic extract of *C. decidua* stem part, while (Fig. 2) and (Table 2) revealed GC/MS data analysis of ethyl acetate fraction of methanolic extract of *C. decidua* stem part.

TLC technique

TLC profile of DCM active fraction

Toluene: ethylacetate: methanol (9:1:1) was the most proper mobile phase among many examined mobile phases for the DCM active fraction (Fig. 3), the isolated spots in the plate (precoated silica gel 60 F254) were seen under daylight, under short UV (254 nm), under long UV (366 nm), were exposed to ammonia vapour and were finally sprayed by vanillin/H2SO4 followed by heating in an oven for 10 minutes.



Figure 2. GC/MS spectrum of ethyl acetate fraction of methanolic extract of C. decidua stem part.

No.	Compound name	Retention time Rt (minute)	Area percentage (%)	Peak area
1	1,2-ethanediol	6.75	1.610	53,426
2	Tetrahydro-5,6,	7.29	11.210	371,137
3	2H-pyran-2-one	8.15	1.490	49,254
5	2-(2-Hydroxyethoxy)- acetamide	9.77	17.520	580,057
6	2-Methyl-2-propenoic	10.47	1.650	54,489
7	acid	11.18	0.330	10,988
8	,2-Methyl benzaldehyde	11.82	2.150	71,314
9	1-Ethoxy-1-Pentoxy-	12.97	1.460	48,453
10	Ethane	14.18	4.320	143,109
11	2-Methoxy-4- Vinvlphenol	14.58	0.570	18,983
12	N-[4-Methoxy-2-(4-	14.97	3.060	101,217
13	Nitrobenzyli	15.69	2.000	66,056
14	heptanoic acid	16.32	0.810	26,649
15	1-(4-hydroxy-3-	16.87	1.100	36,513
16	methoxyphenyl)-2-	17.04	2.890	95,736
17	4-hydroxy-3-methyl	17.61	1.310	43,320
18	benzoic acid	17.75	0.730	24,225
19	3-tetrazol-1-yl propionic	18.98	1.790	59,266
20	acid	19.29	8.130	269,057
21	1-Hepten-4-ol	19.63	2.020	66,893
22	2-[3-hydroxy-4- methoxyphenyl]-	20.98	4.450	147,392
23	semicarbazide	21.17	0.760	25,300
24	1-methyl-4-nitro-	21.49	1.050	34,679
25	benzene	21.59	1.070	35,426
26	2-tridecene	23.37	1.270	42,167
27	ethyl 2-heptynoate	24.71	4.760	157,618
28	1-(1,5-dimethyl-4- hexyl)-benzene	25.34	0.550	18,318
29	N-hexadecanoic acid 2-(2-cyclohexen-1-yl)- cyclohexane 9-octadecenoic acid nonanoic acid Isooctanols 6-chlorohexylacetate acrylic acid hexadecanyl ester 3-N-hexyldelta.9- tetrahydrocannabinol dihydro linalool	27.64	15.840	524,446
	bisabolene epoxide			

Table 2. GC/MS data of ethyl acetate fraction of methanolic extract of *C. decidua* stem part.

TLC profile of ethylacetate active fraction

Several mobile phases were attempted to obtain the best-isolated spots, it was observed that to get the best-



Figure 3. TLC profile of DCM active fraction of methanolic extract of *C. decidua* stem part; (a): The plate as seen in daylight; (b): The plate as seen under short UV (254 nm); (c): The plate as seen under long UV (366 nm); (d): The plate after spraying by vanillin/ H_2SO_4 and heating for 10 minutes in the oven; (e): The plate after exposing to ammonia vapor.



Figure 4. Two dimensional TLC profile of ethylacetate active fraction of methanolic extract of *C. decidua* stem part; the mobile phase was toluene: ethylacetate: formic acid: n-butanol: chloroform (5:4:1:1:0.5) then after 90° rotation, the plate was developed by toluene: ethylacetate: formic acid: n-butanol (5:4:1:1); (a): The plate as seen under short UV (254 nm); (b): The plate as seen under long UV (366 nm); (c): The plate after spraying by vanillin/ H₂SO₄ and heating for 10 minutes in the oven.



Figure 5. HPTLC profile of DCM active fraction of methanolic extract of *C. decidua* stem and marker containing a mixture of standard compounds of oleanolic acid and β -sitosterol; (a): The plate under white light illumination after derivatization by vanillin/ H₂SO₄ reagent; (b): The plate under long UV 366 nm.

isolated spots without tailing, this was achieved by applying two dimensional TLC method (precoated silica gel 60 F254: 20×20 cm) with toluene: ethylacetate: formic acid: n-butanol:



Figure 6. (a): The peak areas of isolated compounds from DCM active fraction of methanolic extract of *C. decidua* stem part by HPTLC; (b): Peak areas of isolated standard compounds from the marker containing oleanolic acid and β -sitosterol by HPTLC.



Figure 7. Three-dimensional graph showing the peak areas of isolated compounds from DCM active fraction of methanolic extract of *C. decidua* stem part and the marker of standard compounds (oleanolic acid and β -sitosterol) by HPTLC.



Figure 8. Spectra comparison of isolated known compounds (oleanolic acid and β -sitosterol) from DCM active fraction of methanolic extract of *C. decidua* stem part and the marker by HPTLC.

chloroform (5:4:1:1:0.5) and then by toluene: ethylacetate: formic acid: n-butanol (5:4:1:1) after rotating the plate 90*o* (Fig. 4).

HPTLC fingerprint profile

The mobile phase applied with DCM active fraction was toluene: ethyl acetate: methanol 9:1:1; while the mobile phase applied with ethylacetate active fraction was toluene: ethylacetate: formic acid: n-butanol 5:4:1:1. For both active fractions, a number of standard compounds with known hepatoprotective and antioxidant activities were selected and developed in each plate (precoated silica gel 60 F254), these selected compounds were rutin, quercetin, kaempferol, ferulic acid, oleanolic acid and β -sitosterol. After development, both plates were developed, and scanned and the peak areas were recorded by using WIN CATS 1.2.3. software program. DCM

Table 3. Rf-values and linear regression data for the calibration curve of oleanolic acid and β -sitosterol (n = 6).

Parameters	Oleanolic acid	β-sitosterol
Linearity range (ng/spot)	200-1,400	200-1,400
Regression equation	Y = 5.54X + 458.64	Y = 7.31X + 756.78
Correlation (r2) coefficient	0.996	0.994
Slope \pm SD	5.53 ± 0.07	7.31 ± 0.10
Intercept \pm SD	458.64 ± 23.65	756.78 ± 2.75
Standard error of slope	0.03	0.04
Standard error of intercept	9.66	22.04
R _f	0.36 ± 0.001	0.54 ± 0.001
LOD* (ng)	43.03	45.69
LOQ** (ng)	130.42	138.47

*LOD: Limit of Detection. **LOQ: Limit of Quantification.

Table 4. Recovery as accuracy studies of the proposed HPTLC method (n = 6).

active fraction revealed the presence of oleanolic acid and β -sitosterol, while ethylacetate active fraction does not show any presence of these selected standard compounds. Hence, the procedure was re-chromatogramed again by applying DCM active fraction with a marker containing a mixture of β -sitosterol and oleanolic acid (Figs. 5–8).

Validation methods in terms of precision, accuracy, and repeatability were performed according to ICH guidelines 2005 (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, which is recommended by regulatory bodies of the European Union, Japan, and the USA), validation methods were applied to confirm that the isolated compounds from DCM active fraction were specifically oleanolic acid and β -sitosterol, and their Rf-values were calculated. Their calibration curves were determined. The recovery, precision, and robustness of the proposed HPTLC method were also determined. In addition, the quantification method was also applied according to ICH guidelines to estimate their concentrations in the DCM active fraction, all results are shown in (Tables 3–7).

In silico docking of selective active compounds

The following table (Table 8) represents the docking binding energy (Kcal/Mol) of the selected active phytochemical compounds with the selected protein ligands responsible for hepatotoxicity.

Figures 9 and 10 display the docking results of hexanoic acid binding to the active sites of 1itb, 6t7v, and 3gc8.

In addition, Figures 11 and 12 display the docking results of 9-octadecenoic acid (Elaidic acid) binding to the active sites of 1itb, 6t7v, and 5azt.

Percent (%) of Oleanolic acid and β-sitosterol	Theoretical concentration of Oleanolic acid and	Concentration found (ng/ band) ± SD		%RSD*		% Recovery	
added to analyte	β-sitosterol (ng/band)	Oleanolic acid	β-sitosterol Oleanolic acid β-sitoster		β-sitosterol	Oleanolic acid	β-sitosterol
0	400	397.08 ± 7.11	393.98 ± 7.31	1.79	1.86	99.27	98.49
50	600	594.26 ± 11.07	590.41 ± 10.79	1.86	1.83	99.04	98.40
100	800	787.36 ± 15.23	792.42 ± 13.47	1.93	1.70	98.42	99.05
150	1,000	983.08 ± 19.19	994.55 ± 14.39	1.95	1.45	98.31	99.46

*%RSD: Relative Standard Deviation.

Table 5. Precision of the proposed HPTLC method (n = 6).

~ .		Oleano	lic acid			β-sito	sterol	
Conc. of standard added	Intra-day precision		Inter-day pre	precision Intra-day prec		ecision Inter-day pre		cision
(ng/band)	Average found conc. ± SD	%RSD	Average found conc. ± SD	%RSD	Average found conc. ± SD	%RSD	Average found conc. ± SD	%RSD
600	598.28 ± 10.49	1.75	589.61 ± 10.17	1.72	592.24 ± 11.39	1.92	589.92 ± 10.67	1.81
800	793.82 ± 14.92	1.88	788.59 ± 13.69	1.73	793.19 ± 14.29	1.80	785.80 ± 13.19	1.68
1,000	992.52 ± 19.38	1.95	984.75 ± 18.17	1.85	992.67 ± 15.67	1.58	988.56 ± 14.83	1.50

Optimization condition	Olean (600 n	olic acid g/band)	β-sitosterol (600 ng/band)		
	SD	%RSD	SD	%RSD	
Mobile phase composition: (Chloroform: Methanol)					
(98:2)	11.77	1.97	9.47	1.60	
(97.5:2.5)	11.68	1.96	9.59	1.62	
(98.5:1.5)	11.61	1.95	9.67	1.63	
Mobile phase volume (for saturation)					
(18 ml)	11.87	1.99	8.28	1.40	
(20 ml)	11.79	1.98	8.53	1.44	
(22 ml)	11.73	1.97	8.67	1.46	
Duration of saturation					
(10 minutes)	11.67	1.97	8.89	1.50	
(20 minutes)	11.59	1.95	8.73	1.47	
(30 minutes)	11.54	1.94	8.69	1.46	

Table 6. Robustness of the proposed HPTLC method (n = 6).

Table 7. Oleanolic acid and β -sitosterol content in DCM active

fraction of methanolic extract of *C*. *decidua* stem part (n = 3).

Oleanelic acid content (µg/mg of	β-sitosterol content (μg/mg of			
dried weight of the fraction)	dried weight of the fraction)			
7.73 ± 0.29	9.21 ± 0.42			

Table 8. Docking binding energy (Kcal/Mol) of active phytochemical compounds on targeted receptors.

	9,12,15-Octadecatrieonic acid	9-Octadecenoic acid (Elaidic acid)	β-Sitosterol	Dihydrolinalool	Hexadecanoic acid	Oleanolic acid	Silymarin
1itb	-7.7859	-8.0829	-7.0777	-7.0689	-8.1568	-7.1739	-10.1830
1nfi	-5.7901	-6.0980	-6.4031	-5.2952	-7.1121	-8.4427	-11.3642
1uki	-6.5849	-7.1118	-7.3536	-7.0116	-6.6529	-10.6087	-10.0683
1vkx	-7.0824	-6.6916	-7.9115	-8.6269	-7.8919	-9.2096	-12.3947
2az5	-6.3023	-6.5902	-6.3452	-5.9050	-6.6215	-6.5945	-12.0840
3gc8	-7.6065	-6.9061	-7.9052	-5.1004	-8.4922	-6.7006	-11.8550
5azt	-7.6869	-7.6441	-5.7348	-6.0396	-5.8047	-6.7433	-9.6373
4s0t	-8.1143	-8.4593	-6.5328	-4.8878	-6.6851	-7.7265	-12.0231
7y1r	-7.0614	-7.4744	-5.5658	-	-7.6023	-5.6361	-11.7115
6t7v	-6.4802	-8.5313	-6.0025	-6.6786	-8.7252	-7.8783	-10.1840
1p9m	-7.1502	-7.1046	-8.0519	-5.1414	-7.6273	-7.7065	-10.6661



Figure 9. Docking results of hexadecanoic acid binding to the active sites of litb: predicted interactions and binding modes.



Figure 10. Docking results of hexadecanoic acid binding to the active sites of (a): 6t7v; and (b): 3gc8: Predicted interactions and binding modes.



Figure 11. Docking results of 9-octadecenoic acid (elaidic acid) binding to the active sites of 1itb: Predicted interactions and binding modes.



Figure 12. Docking results of 9-octadecenoic acid (elaidic acid) binding to the active sites of (a): 6t7v; and (b): 5AZT: Predicted interactions and binding modes.

Furthermore, Figures 13 and 14 depict the docking results of oleanolic acid binding to the active sites of 1nfi, 1uki, and 1vkx.

The docking result of β -sitosterol binding to the active site of 1p9m as well as the docking result of 9,12,15-octadecatrienoic acid binding to the active site of 5azt are represented in Figures 15 and 16, respectively.

litb: IL-1 receptor; 1nfi: p65 (NF-kappa B transcription factor binds to DNA as a heterodimer of 65 kDa); 1uki: inhibits JNK; 1vkx: the crystal structure of NF-kb; 2az5: TNF- α , 3gc8: p38 (p38 mitogen-activated protein kinases); 5azt: PPAR- α (Peroxisome proliferator-activated receptor-alpha); 4s0t: PXR (Pregnene X receptor factor); 7y1r: TGF- β (Transforming



Figure 13. Docking results of oleanolic acid binding to the active sites of (a): 1nfi; and (b): 1uki: Predicted interactions and binding modes.



Figure 14. Docking result of oleanolic acid binding to the active site of 1vkx: predicted interactions and binding modes.

Growth Factor-beta); 6t7v: Nrf2 (Nuclear factor erythroid 2-related factor 2); 1p9m: IL-6 α receptor.

DISCUSSION

Capparis decidua stem part has many traditional uses, treatment of jaundice is one of its traditional uses [13,14]. The hepatoprotective activity of the stem part of *C. decidua* was tested against CCl_4 -induced hepatotoxicity rats, the methanolic extract revealed significant hepatoprotective activity, this alcoholic extract was fractionated successively by DCM, ethyl acetate, *n*-butanol, and aqueous fractions, only DCM and ethyl acetate fractions revealed strong hepatoprotective and antioxidant activities [14], hence they were both selected in this study to determine and prove the active compounds by using GC/MS, HPTLC finger print profile and *in silico* docking techniques.

GC/MS chromatogram for both DCM and ethyl acetate fractions showed presence of 25 and 29 peaks, respectively, indicating presence of 25 and 29 compounds; in DCM fraction (Fig. 1 and Table 1), the highest percentage was n-hexadecanoic acid (Rt = 19.31, 24.54%), this compound was also present in ethyl acetate fraction (Rt = 19.29, 8.13%), which ranked as 4th compound over 29 compounds in its amount content (Fig. 2 and Table 2), the first three compounds were an oxygenated hydrocarbons; a previous study had analysed the hepatoprotective active ethanolic extract of Cryptolepis buchanani stem part against paracetamol-induced hepatotoxicity in rats by GC/MS, their results showed dominant presence of oxygenated and phenolic hydrocarbons, in which many of these compounds have hepatoprotective, antioxidant and anti-inflammatory properties, the interesting point was the presence of high amount of *n*-hexadecanoic



Figure 15. Docking result of beta-sitosterol binding to the active site of 1p9m: predicted interactions and binding modes.



Figure 16. Docking result of 9,12,15-octadecatrienoic acid binding to the active site of 5azt: predicted interactions and binding modes.

acid which ranked as 3rd over 20 compounds (11.44%), also octadecanoic acid was also observed in their study and it was detected in our ethyl acetate fraction (Rt = 20.98, 4.45%) [15]. Moreover, searching in the literature for any biological activities of the detected compounds in DCM and ethyl acetate fractions showed that hexadecanoic acid, 9,12-octadecadienoic acid, and linalool have hepatoprotective, antioxidant, antiinflammatory, and immunomodulatory properties [16-18], our fractions showed the presence of hexadecanoic acid, 9-octadecenoic acid, 9,12,15-octadecatrienoic acid and dihydro linalool. Hexadecanol and octadecanol were identified and characterized before in C. decidua [19], also hexadecanoic acid and 9,12,15-octadecatrienoic acid were detected before in C. decidua seeds [9,11], so this is the first time to identify hexadecanoic acid and 9,12,15-octadecatrieonic acid in C. decidua stem part. Hence, we can say that the hepatoprotective and antioxidant activities of DCM and ethyl acetate fractions may probably be due to the presence of these compounds and other compounds like phenolic hydrocarbons, oxygenated hydrocarbons and carboxylic acids which were detected in both fractions, so further analysis by using other chromatographic techniques and in silico docking method are recommended to prove our findings.

HPTLC is considered an important technique used in the standardization and quality control of phytopharmaceuticals, any medicinal plant should be authenticated to exclude adulteration and HPTLC can be used for this purpose, also checking the presence of active constituents and quantifying their concentrations are very important in the preparation of phyto-pharmaceuticals, these are also achieved by HPTLC [20]. TLC technique was firstly used to choose the most proper mobile phases (Figs. 3 and 4); to identify the

active compounds responsible for hepatoprotective activity in both fractions, we selected some known hepatoprotective and antioxidant active standard compounds and used them as markers, it was revealed that DCM active fraction contains β -sitosterol and oleanolic acid (Figs. 5–8), while ethylacetate active fraction does not showed presence of tested standard compounds, so it was concluded that the hepatoprotective activity of ethylacetate active fraction was due to presence of compounds other than tested standard compounds, and hence both fractions are not totally identical. The Rf-values of β -sitosterol and oleanolic acid were 0.54 and 0.36, respectively. The identification of β -sitosterol and oleanolic acid occurred in DCM active fraction were proved by validation and quantifying methods according to ICH guidelines 2005 [21]; generally, validation method is always repeated in terms of precision and accuracy to confirm that the identified compounds are really β -sitosterol and oleanolic acid, so the linearity range used for β -sitosterol and oleanolic acid were 200–1,400 ng/spot with r2values = 0.994 and 0.996, respectively (n = 6), their calibration curves and regression equations were determined as the data shown in (Table 3), the limit of detection of β -sitosterol and oleanolic acid were 45.69 and 43.03 ng, respectively; the mean percent recovery of β -sitosterol and oleanolic acid at different concentrations were 98.85% and 98.76%, respectively (Table 4); also the method was precise because the percentages of relative standard deviation (%RSD) of intra-day precision of β -sitosterol and oleanolic acid were ranged between 1.58–1.92 and 1.75-1.95, respectively, with ascending concentrations (i.e., 600, 800, and 1,000 ng/band), while the %RSD of interday precision of both compounds were ranged between 1.50-1.81 and 1.72-1.85, respectively, with the same ascending concentrations (Table 5); the robustness of the proposed HPTLC technique was also precise after using different compositions of the mobile phase chloroform: methanol with different volumes and different times of saturation (n = 6) as shown in (Table 6). By using the quantifying method, and with the aid of the obtained calibration curves, it was observed that the mean contents (w/w) of β -sitosterol and oleanolic acid were 9.21 and 7.73 µg/ mg of dry fraction weight, respectively (Table 7). β -sitosterol and oleanolic acid are steroidal (phytosterol) and pentacyclic triterpenoids, respectively, sometimes both compounds may occur in glycosidal form in the form of saponins [22]. They are widely distributed and abundant in many plants [23,24].

 β -sitosterol was isolated before from the seeds, fruit husks, flowers, roots, and root barks of *C. decidua* [25], also it was identified and quantified before by HPTLC from the stem part of *C. decidua* [26], it was proved in many studies that it possesses strong antioxidant and anti-inflammatory properties with moderate hepatoprotective activity, also it possesses anti-pyretic, immuno-modulatory, anti-diabetic, hypocholesterolaemic, anti-bacterial, and anti-cancer properties [18,25,27].

Many studies proved that oleanolic acid possesses strong hepatoprotective activity; in addition, it has antioxidant, anti-inflammatory, immuno-modulatory, α -glucosidase inhibitory, anti-hyperlipidemic, anti-bacterial, anti-fungal, anti-viral, anti-HIV, and anti-cancer properties [25,27,28], in China, oleanolic acid was marketed in oral formulations for the treatment of various liver disorders [28], it was suggested that its mode of action as hepatoprotective activity is achieved by inhibiting toxicants activation and enhancing the body defense system, this is an interpretation that the hepatoprotective, antioxidant and anti-inflammatory properties of oleanolic acid are synergistic triple strength for treatment of many liver disorders [24]. According to our knowledge, this is the first time to identified oleanolic acid in C. decidua stem part. Therefore, we suggest that the hepatoprotective and antioxidant activities of DCM fraction are probably due to the presence of oleanolic acid, β-sitosterol, hexadecanoic acid, 9,12,15-octadecatrienoic acid, and other phenolic hydrocarbon acids, while we suggest the hepatoprotective and antioxidant activities of ethyl acetate fraction is probably due to the presence of hexadecanoic acid, 9-octadecenoic acid, and other phenolic hydrocarbon acids, to get the whole clear picture, further analysis such as liquid chromatography-mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR) are recommended to identify and characterize other isolated compounds from both DCM and ethylacetate active fractions.

Generally, triterpenoids (such as β -sitosterol and oleanolic acid) are very important natural hepatoprotective agents, because about 350 natural triterpenoidal compounds with hepatoprotective activity were reviewed between 1975 and 2016 [29], so these important natural compounds should be considered in the field of drug discovery and design for searching for new compounds with potential hepatoprotective activity.

The selected active phytochemical compounds for in silico docking were 9,12,15-octadecatrieonic acid, 9-octadecenoic acid (elaidic acid), β -sitosterol, dihydrolinalool, hexadecanoic acid, and oleanolic acid; silymarin was selected as a positive control because it is known hepatoprotective agent. The selected proteins were according to their mechanisms of action either by activation or signaling transcriptions which finally lead to liver injury, some of these proteins are inflammatory mediators, so by inhibiting these proteins targets by some drugs is considered potential for improving liver injury which was stimulated by free radicals and/or some foreign toxic substances such as CCl, and paracetamol [30]. The negatively charged binding energy (Kcal/Mol) indicates that the compound has low energy binding and, hence possesses hepatoprotective properties, all tested phyto-chemical compounds showed negatively charged binding energy which means that they have hepatoprotective activity but with various degrees, silymarin was the lowest binding energy with all targeted proteins except against 1uki protein (JNK inhibitor) (Table 8).

Hexadecanoic acid, being a hydrophobic molecule, may interact with hydrophobic regions or residues in the proteins. This could involve interactions with nonpolar amino acid side chains or hydrophobic pockets within the protein structures. Van der Waals forces, including London dispersion forces, can occur between hexadecanoic acid and the protein. These forces contribute to the overall stability of the complex through attractive interactions between the electron clouds of hexadecanoic acid and the protein's atoms. Hexadecanoic acid contains a carboxyl group (–COOH), which can potentially form hydrogen bonds with specific amino acid residues such as arginine in the protein. Hexadecanoic acid contains a carboxylic acid group, which could potentially form hydrogen bonds with arginine residues in the active site of 6t7v protein (Nrf2) (Fig. 10a). Hexadecanoic acid has the potential to engage in hydrogen bonding with specific amino acid residues in the 3gc8 protein (p38 mitogen-activated protein kinase) (Fig. 10b), along with Dipole–Dipole interactions, this is because the carbonyl group possesses a substantial dipole moment resulting from the difference in electronegativity between the oxygen and carbon atoms. In addition, the oxygen atom within the carbonyl group can function as a hydrogen bond acceptor.

9-octadecenoic acid (elaidic acid), being a fatty acid with a hydrophobic hydrocarbon tail, may interact with hydrophobic residues or regions in the active site of 1itb, 6t7v, and 5azt proteins (IL-1 receptor, Nrf2, and peroxisome proliferator-activated receptor- α (PPAR- α), respectively) (Figs. 11 and 12). These interactions occur when nonpolar regions of elaidic acid interact with nonpolar amino acid side chains, forming a hydrophobic pocket. Hydrophobic interactions can play a crucial role in the binding affinity and stability of the complex. Elaidic acid may form hydrogen bonds with asparagine in the active site of IL-1 receptor (1itb), hydrogen bonding interactions can provide additional stability to the complex. Van der Waals interactions can occur due to temporary fluctuations in electron distribution and can contribute to the overall stability of the fatty acid-protein complex. The docking results revealed distinct binding modes for elaidic acid and hexadecanoic acid within the active site of the IL-1 receptor. Elaidic acid formed a combination of hydrophobic interactions, hydrogen bonding, and Van der Waals contacts. The trans double bond in elaidic acid allowed for favorable π -stacking interactions with aromatic residues in the active site of the IL-1 receptor, contributing to the stability of the complex. In contrast, hexadecanoic acid exhibited primarily hydrophobic interactions with IL-1 receptors. The straight-chain structure of hexadecanoic acid allowed for extensive hydrophobic contacts with nonpolar amino acid residues within the binding pocket of the IL-1 receptor. Van der Waals interactions played a critical role in stabilizing the complex, while the absence of a double bond limited the potential for π -stacking interactions observed with elaidic acid. The differential interactions of elaidic acid and hexadecanoic acid with IL-1 receptor suggest distinct binding modes and potential functional implications. The trans double bond in elaidic acid introduces geometric constraints and enables specific interactions that may influence its biological activity. On the other hand, the lack of a double bond in hexadecanoic acid allows for a more extended hydrophobic surface, facilitating favorable hydrophobic interactions. Elaidic Acid contains a carboxylic acid group (-COOH), which could potentially form hydrogen bonds with Valine residues in the active site of 6t7v protein (Nrf2), and glutamine residues in 5azt protein (PPAR- α). It is important to note that elaidic acid is a dietary fatty acid and not a known inhibitor of COX-2 like Celecoxib. Nevertheless, considering general principles, the following interactions and SAR could be explored:

Regarding SAR, it is important to note that elaidic acid is not specifically designed as a COX-2 inhibitor, and its SAR as a ligand for COX-2 has not been extensively studied; modifications to the fatty acid chain length, the presence of double bonds, or the introduction of functional groups could be explored to assess their effects on COX-2 binding and inhibitory activity.

Oleanolic acid, being a small molecule, can potentially interact with proteins through various mechanisms, including hydrogen bonding, hydrophobic interactions, and electrostatic interactions. Oleanolic acid contains a carboxylic acid group (-COOH), which may establish hydrogen bonds with glutamic acid residues in the active sites of both the 1nfi and 1uki proteins (p65 and JNK inhibitor, respectively) (Fig. 13), as well as the arginine residue in the 1vkx protein (NF-kb) (Fig. 14). Dipole–Dipole Interactions are possible with oleanolic acid because of the difference in electronegativity between the oxygen and carbon atoms; the carbonyl group has a significant dipole moment. Furthermore, the oxygen atom in the carbonyl group can act as a hydrogen bond acceptor.

The docking studies between beta-sitosterol and 1p9m (IL-6 α) (Fig. 15) provide insights into their potential binding interactions. Although experimental validation is necessary, the analysis of the docking results can offer a preliminary understanding of the structure activity relationship (SAR) and possible interactions. One possible interaction is the formation of hydrogen bonds between the hydroxyl group (–OH) of beta-sitosterol and glutamic acid within the binding site of the IL-6 α receptor. These hydrogen bonds can play a crucial role in stabilizing the ligand-protein complex. In addition to hydrogen bonding, hydrophobic interactions are likely to occur between the hydrophobic regions of beta-sitosterol and the hydrophobic residues of the IL-6 α receptor. These interactions involve nonpolar groups and contribute to the overall binding affinity and stability of the complex.

The carboxylic acid group (-COOH) of 9,12,15-octadecatrienoic acid has the capacity to create hydrogen bonds with the glutamic acid found in 5azt protein (PPAR- α) (Fig. 16).

The results obtained by *in silico* docking are useful prediction tools for future plans of drug development, so we recommend considering our active compounds for drug development (SAR) on the tested proteins, proteins which are responsible for hepatotoxicity, also we recommend to consider and examine any presence of synergism (as hepatoprotective and antioxidant activities) if these compounds were combined together as in our case in DCM and ethyl acetate fractions of the methanolic extract of *C. decidua* stem.

CONCLUSION

GC/MS chromatogram for both DCM and ethyl acetate fractions showed the presence of 25 and 29 compounds, respectively, our fractions showed the presence of considerable contents of hexadecanoic acid, 9-octadecenoic acid, 9,12,15-octadecatrienoic acid and dihydrolinalool, which they have various degrees of hepatoprotective and antioxidant activities, this is the first time to identify hexadecanoic acid in *C. decidua* stem.

 β -sitosterol and oleanolic acid were isolated and identified from the DCM fraction by HPTLC, the two lead triterpenoidal natural compounds are known hepatoprotective

and antioxidant agents, this is the first time to isolate and identify oleanolic acid from *C. decidua* stem, this validated HPTLC fingerprint profile method can be used for standardization and quality control of the active hepatoprotective DCM fraction, the two lead compounds should be considered in the field of drug development and design of hepatoprotective activity, LC/MS and NMR methods should also be considered in the future to identify other unknown compounds present in DCM and ethylacetate fractions.

All tested phyto-chemical compounds identified by GC/MS and HPTLC revealed negatively charged binding energy by in silico docking, which means that they have hepatoprotective activity but with various degrees. Hexadecanoic acid showed significant predicted binding properties with Nrf2, p38 mitogen-activated protein kinase, and IL-1 receptor proteins. 9-octadecenoic acid (elaidic acid) showed significant predicted interactions with IL-1 receptor, Nrf2, and PPAR-α proteins. Oleanolic acid showed significant predicted binding with p65, JNK, and NF-kb. Hexadecanoic acid showed significant predicted binding properties with Nrf2, p38 mitogen-activated protein kinase, and IL-1 receptor proteins. 9-octadecenoic acid (elaidic acid) showed significant predicted interactions with IL-1 receptor, Nrf2, and PPAR-α proteins. Oleanolic acid showed significant predicted binding with p65, JNK, and NF-kb. β-sitosterol showed significant predicted interactions with IL-6a protein, while 9,12,15-octadecatrienoic acid revealed significant binding with PPAR- α protein. So we recommend considering our active compounds for the field of drug development (SAR) and the presence of synergism if they are combined and administered together.

ACNOWLEDGEMENT

The authors extend their appreciation to Prince Sattam bin Abdulaziz University for funding this research work through the project number (PSAU/2023/03/25508).

AUTHOR CONTRIBUTIONS

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. All the authors are eligible to be an author as per the International Committee of Medical Journal Editors (ICMJE) requirements/guidelines.

CONFLICTS OF INTEREST

The authors report no financial or any other conflicts of interest in this work.

ETHICAL APPROVALS

This study does not involve experiments on animals or human subjects.

DATA AVAILABILITY

All data generated and analyzed are included in this research article.

PUBLISHER'S NOTE

This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.

REFERENCES

- Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(01):151–71. doi: https:// doi.org/10.1016/j.jhep.2018.09.014
- Reddy VJS, Deval Rao G, Mallikarjuna K. A review on hepatoprotective activity of some medicinal plants. Int J Innov Pharm Res. 2014;5(02):395–404.
- Kumar SV, Sanjeev T, Ajay S, Kumar SP, Anil S. A review on hepatoprotective activity of medicinal plants. Int J Adv Res Pharm Biosci. 2012;2(01):31–8.
- 4. Jannu V, Baddam PG, Boorgula AK, Jambula SR. A review on hepatoprotective plants. Int J Drug Dev Res. 2012;4(03):1–8.
- Dhakad P, Sharma P, Kumar S. A review on ethnobiological and medicinal potential of Capparaceae family plant: *Capparis decidua* (Forssk.) Edgwe. Adv Pharmacol Pharm. 2016;4(03):27–39. doi: https://doi.org.10.13189/app.2016.040302
- Mohammed MS, Khalid HS, Muddathir AK, Siddiqui NA, Ali M. A novel germacranolide sesquiterpene lactone with anti-inflammatory effect from *Capparis decidua* (Forsk.). Int J Res Pharm Chem. 2012;2(04):1073–7.
- Dev SK, Shukla A, Choudhury PK, Singh GK. Analgesic and antinociceptive activity of hydroethanolic extract of *Capparis decidua* Linn. Asian J Pharm Pharmacol. 2015;1(01):40–4.
- Mohammed MS, Khalid HS, Muddathir AK, Tahir KEH, Osman B, Osman WJA, *et al.* Effect of two sesquiterpene lactones from *Capparis decidua* (Forsk.) on arachidonic acid and adenosine diphosphateinduced platelets aggregation. J Phytopharm. 2014;3(03):176–9.
- Zia-El-Haq M, Cavar S, Qayum M, Imran I, de Feo V. Compositional studies: antioxidant and anti-diabetic activities of *Capparis decidua* (Forssk.) Edgwe. Int J Mol Sci. 2011;12:8846–61. doi: https:// doi:10.3390/ijms12128846
- Dahiya R, Vaghela JS. Evaluation of anti-asthmatic activity of Capparis decidua. Asian J Pharm Clin Res. 2022;15(02):94–7. doi: https://dx.doi.org/10.22159/ajpcr.2022v15i2.43378
- Nazar S, Hussain MA, Khan A, Muhammad G, Tahir MN. *Capparis decidua* Edgwe (Forssk.): a comprehensive review of its traditional uses, phytochemistry, pharmacology and nutrapharmaceutical potential. Arab J Chem. 2020;13:1901–16. doi: https://doi.org/10.1016/j.arabjc.2018.02.007
- 12. Rasheed HMF, Jabeen Q. Pharmacological role of *Capparis decidua* (Forssk.) Edgwe in preventing cyclophosphamide-induced myelosuppression and modulating innate and adaptive immune response. Dose Response. 2022;20(03):15593258221123672. doi: https://doi.org.10.1177/15593258221123672
- Ali SA, Al-Amin TH, Mohamed AH, Gameel AA. Hepatoprotective activity of aqueous and methanolic extracts of *Capparis decidua* stem against carbon tetrachloride induced liver damage in rats. J Pharmacol Toxicol. 2009;4(04):167–72.
- Mirghani M, Khalid HS, Mohammed MS, Mohamed AB, Ali A, Osman W, *et al.* Hepatoprotective and free radical scavenging activities of methanol extract fractions of *Capparis decidua* Edgwe (Forssk.) (Capparidaceae). Afr J Pharm Pharmacol. 2020;14(08):316– 30. doi: https://doi.org.10.5897/AJPP2020.5180
- Padmalochana K, Rajan MSD, Lalitha R, Sivasankari H. Evaluation of the antioxidant and hepatoprotective activity of *Cryptolepis buchanani*. J Appl Pharm Sci. 2013;3(02):099–104. doi: https://doi. org. 10.7324/JAPS.2013.30217
- Shah MD, D'Souza UJA, Iqbal M. The potential protective effect of *Commelina nudiflora* L. against carbon tetrachloride (CCl4)-induced hepatotoxicity in rats, mediated by suppression of oxidative stress and inflammation. Environ Health Prev Med. 2017;22(01):1–19. doi: https://doi.org.10.1186/s12199-017-0673-0

- Thakur AV, Ambwani S, Ambwani TK, Ahmad AH, Rawat DS. Evaluation of phytochemicals in the leaf extract of *Clitoria ternatea* Willd. Through GC/MS analysis. Trop Plant Res. 2018;5:200–6. doi: https://doi.org.10.22271/tpr.2018.v5.i2.025
- Maran BAV, Iqbal M, Gangadaran P, Ahn BC, Rao PV, Shah MD. Hepatoprotective potential of Malaysian medicinal plants: a review on phytochemicals, oxidative stress and antioxidant mechanisms. Molecules. 2022;27(05):1533. doi: https://doi.org/10.3390/ molecules27051533
- Ali MZ, Mehmood MH, Saleem M, Akash MSH, Malik A. Pharmacological evaluation of *Euphorbia hirta*, *Fagonia indica* and *Capparis decidua* in hypertension through *in-vivo* and *in-vitro* assays. Heliyon. 2021;7(10):e08094. doi: https://doi.org. 10.1016/j. heliyon.2021.e08094
- Mohamed NS, Mohamed MS, Mothana RA, Osman WJ, Khalid HS. HPTLC fingerprint profiles and UPLC-MS identification of potential antioxidant fractions and compounds from *Ambrosia maritima* L. and *Ammi majus* L. Afri J Biotechnol. 2020;19(05):249–58. doi: https://doi.org.10.5897/AJB2020.17114
- Anonymous. ICH harmonized tripartite guideline (2005) validation of analytical procedures: text and methodology Q2(R1). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, November 2005. Available from: https://www.fda. gov/regulatory-information/search- fda-guidance- documents/q2r1validation-analytical-procedures-text-and-methodology-guidanceindustry.
- Castellano JM, Ramos-Romero S, Perona JS. Oleanolic acid: extraction, characterization and biological activity. Nuterients. 2022;14(03):623. doi: https://doi.org/10.3390/nu14030623
- Bahat AH, Alia A, Rather GM, Kumar B. Isolation and characterization of beta-sitosterol from the rhizomes of *Arisaema utile* and its evaluation of antioxidant activity. Int J Sci Res Biol Sci. 2019;6(02):111–8. doi: https://doi.org/10.26438/ ijsrbs/v6i2.111118
- Wan XL, Lu YF, Xu SF, Wu Q, Liu J. Oleanolic acid protects against the hepatotoxicity of D-galactosame plus endotoxin in mice. Biomed Pharmacother. 2017;93:1040–6. doi: https://doi.org.10.1016/j. biopha.2017.07.045
- Sharma P, Sharma DK. Medicinal value of three common plants of Rajasthan, India: review. J Med Plants Stud. 2018;6(01):096–101.

- Rathee S, Mogla OP, Rathee P, Rathee D. Quatification of β-sitosterol using HPTLC from *Capparis decidua* (Forssk.) Edgwe. Der Pharma Chem. 2010;2(04):86–92.
- Balogun O, Ojerinde OS, Afolabi EO, Alemika TE. Isolation and characterization of β-sitosterol, oleanolic, 19-dehydroursolic and yarumic acids from *Plectransthus esculentus* leaves and tubers. J Pharm Bioresour. 2022;19(01):43–50. doi: https://dx.doi. org/10.4314/jpb.v19i1.6
- Liu J. Review article: pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol. 1995;49(02):57–68. doi: https://doi. org.10.1016/0378-8741(95)90032-2
- Xu GB, Xiao YH, Zhang QY, Zhou M, Liao SG. Hepatoprotective natural triterpenoids. Eur J Med Chem. 2018;145:691–716. doi: https://doi.org.10.1016/j.ejmech.2018.01.011
- 30. Ullah H, Khan A, Bibi T, Ahmad S, Shehzad O, Ali H, *et al.* Comprehensive *in vivo* and *in silico* approaches to explore the hepatoprotective activity of poncirin against the paracetamol toxicity. Naunyn Schmiedebergs Arch Pharmacol. 2022;395(02):195–215. doi: https://doi.org.10.1007/s00210-021-02192-1

How to cite this article:

Osman W, Mirghani M, Mohamed M, Sherif A, Ashour A, Sweilam S, Subki H. Chromatographical fingerprint analysis, in *silico* investigation, and identification of hepatoprotective active compounds from *Capparis decidua* Edgwe (Forssk.). J Appl Pharm Sci. 2024;14(08):112–124.